Key facts
- Vizgen’s last known valuation is $379.7M (Apr 2022).
- It has raised $184.2M across 6 recorded rounds; the latest was Early Stage VC ($47.8M) in Dec 2025.
- Notable investors include ARCH Venture Partners, M Ventures, Harvard University, Sofina, Tao Capital Partners — 10 tracked in total.
- Vizgen has filed 5 Form Ds with the SEC since 2019, most recently Oct 2025 ($3.5M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Vizgen
Funding rounds
6 roundsAbout Vizgen
Developer of biomolecule profiling technology designed to bring new insight into biological systems and disease. The company's technology focuses on unlocking the power of spatially resolved, single-cell gene expression profiling in intact tissue slices using spatial gene profiling measurements, enabling medical researchers to efficiently interrogate biology on a systems scale.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 130
- Website
- vizgen.com/
- Ownership
- Privately Held (backing)
Vizgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vizgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vizgen in its N-PORT filings yet. We sweep new filings monthly.